Biotech Values

[DewDiligence]

GILD—As stated in #msg-98511426, the main source of uncertainty in GILD’s profitability in 2017 and beyond depends on whom you ask. Currently, most people think GILD’s HCV franchise is the paramount issue for longs to worry about; I think they’re wrong and that GILD’s HIV franchise is the bigger concern. Regardless, this debate can’t be settled today, next week, or next month.